Aluminium-related osteodystrophy and desferrioxamine treatment: role of phosphorus

Publisher Website
Google Scholar
Abstract
We investigated (1) the prevalence of aluminium overload among 96 patients with symptomatic bone disease haemodialysed from 1987 to 1989 in the Sao Paulo area, Brazil; (2) the effect of 6 months desferrioxamine (DFO) treatment (1–2 g/week). All patients underwent a first bone biopsy. Aluminium overload (extent of stainable bone aluminium more than 20% trabecular surface) was observed in 74 of 96 patients. Forty overloaded patients were divided into patients with high bone formation rate (BFR) (group 1; n=17) and patients with low BFR (group 2; n=23), and had a second biopsy after DFO therapy. In both groups aluminium surface was reduced after treatment (PPPPPPP<0.01) DFO. The histological features of group 2a patients resembled hypophos-phataemic osteomalacia, those of group 2b patients aluminium osteodystrophy. These data show a high prevalence of aluminium overload in Brazilian patients. Low-dose DFO therapy was safe, decreased bone pain, prevented fractures, and reduced stainable bone aluminium. Bone lesions only partially improved, suggesting that low phosphorus intake and/or plasma calcitriol concentrations may have prevented improvement of bone formation and mineralization.

This publication has 0 references indexed in Scilit: